MLTX Latest Headlines

Buy Rating on MoonLake: Sonelokimab’s Differentiated IL-17 Profile and Late-Stage HS Opportunity Support $40 Target

at www.tipranks.com (Wed, 15-Apr 6:25 AM)

Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention

at www.tipranks.com (Tue, 14-Apr 10:04 PM)

Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics

at www.tipranks.com (Tue, 14-Apr 7:28 AM)

MoonLake's Sonelokimab Achieves 62% HiSCR75 Response at 40 Weeks—Setting a New Benchmark in Hidradenitis Suppurativa Clinical Trials

Market Chameleon (Mon, 30-Mar 9:18 AM)

MoonLake’s Sonelokimab Shows Over 80% Patient Improvement in Phase 2 axSpA Trial, Bolstering Pipeline Strength

Market Chameleon (Mon, 23-Feb 7:06 AM)

Fast Track Designation Positions MoonLake’s Sonelokimab for Accelerated Path in PPP as Major 2026 Milestones Approach

Market Chameleon (Mon, 2-Feb 8:42 AM)